Publications by authors named "Mathew Matthen"

Claim this Profile
I
INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.
John F Hilton, Patrick A Ott, Aaron R Hansen, Zujun Li, Matthen Mathew

Cancer Immunol Immunother· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors.
Shoiab Bukhari, Brian S Henick, Robert J Winchester, Shalom Lerrer, Kieran Adam, Matthen Mathew

Cell Rep Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion.
Xun Wu, Yi-Shing Lisa Cheng, Mathew Matthen, Angela Yoon, Gary K Schwartz

J Exp Clin Cancer Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extracellular Vesicles as Biomarkers in Cancer Immunotherapy.
Matthen Mathew, Mariam Zade, Nadia Mezghani, Romil Patel, Yu Wang

Cancers (Basel)· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and outcomes of lung cancer in solid organ transplant recipients.
Lanyi Nora Chen, John Spivack, Thu Cao, Anjali Saqi, Luke J Benvenuto, Matthen Mathew

Lung Cancer· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining chemotherapy with PD-1 blockade in NSCLC.
Matthen Mathew, Thomas Enzler, Catherine A Shu, Naiyer A Rizvi

Pharmacol Ther· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1 as a biomarker in NSCLC: challenges and future directions.
Matthen Mathew, Rachael A Safyan, Catherine A Shu

Ann Transl Med· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of angiotensin II-mediated cardiac remodeling by the MEF2A target gene Xirp2.
Sarah A McCalmon, Danielle M Desjardins, Saad Ahmad, Katharine S Davidoff, Christine M Snyder, Matthen Mathew

Circ Res· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myomaxin is a novel transcriptional target of MEF2A that encodes a Xin-related alpha-actinin-interacting protein.
Hsuan-Ting Huang, Ondra M Brand, Matthen Mathew, Christos Ignatiou, Elizabeth P Ewen

J Biol Chem· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis